Kiniksa Pharmaceuticals International (KNSA) Q3 2026 earnings summary

Executive summary

• Q3 2026 ARCALYST revenue was $286.0M versus $180.9M a year earlier; net income rose to $47.3M from $18.4M.

• 2026 ARCALYST revenue guidance increased to $1.045B-$1.050B as adoption grew.

• PASTORALE, the pivotal Phase 3 KPL-387 trial, was enrolling and dosing; data are expected in H2 2027.

Financial highlights

• Q3 revenue was $286.0M versus $180.9M; 9M revenue was $743.8M versus $475.4M.

• Q3 operating income was $54.2M versus $24.0M, and net income was $47.3M versus $18.4M.

• Q3 R&D expense was $32.8M versus $24.2M; SG&A was $65.4M versus $49.1M.

• ARCALYST collaboration operating profit increased to $211.6M from $126.6M; collaboration expense was $105.8M versus $63.3M.

• 9M operating cash flow was $144.9M versus $84.1M.

Outlook and guidance

• 2026 ARCALYST net revenue guidance rose to $1.045B-$1.050B from $980M-$995M.

• 2026 R&D expense guidance was $160M-$170M and SG&A guidance was $270M-$280M; the current operating plan was expected to remain annually cash-flow positive.

• KPL-387 Phase 3 data are expected in H2 2027, with potential commercialization targeted for 2028-2029.

• KPL-1161's Phase 1 first-in-human trial was expected to begin by year-end 2026, targeting quarterly subcutaneous dosing.